It has been about a month since the last earnings report for Inovio Pharmaceuticals (INO - Free Report) . Shares have lost about 0.6% in that time frame, outperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Inovio due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
Inovio Q3 Loss Narrower Than Expected, Revenues Meet
Inovio incurred a loss of 27 cents in the third quarter of 2018, narrower than both the Zacks Consensus Estimate of a loss of 32 cents and the year-ago loss of 40 cents.
Inovio generated revenues of $2 million in third-quarter 2018, in line with the Zacks Consensus Estimate. However, revenues decreased 23% from the year-ago quarter’s figure of $2.6 million due to some accounting adjustments.
Research and development expenses decreased 14.1% to $21.9 million due to accounting adjustment and lower expenses related to the DARPA Ebola grant.
General and administrative expenses increased 7.9% to $6.8 million in the third quarter.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed an upward trend in fresh estimates.
At this time, Inovio has a subpar Growth Score of D, however its Momentum Score is doing a lot better with a B. However, the stock was allocated a grade of F on the value side, putting it in the lowest quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Estimates have been trending upward for the stock, and the magnitude of this revision looks promising. It comes with little surprise Inovio has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.